持续的脑雾与COVID-19患者的严重症状群有关。

IF 0.5 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
José Ramón Lanz-Luces, Héctor Aceituno, Fernando Quiroz-Bravo, Felipe Rodríguez-Flores, Marcela Osores-Espinoza, Dairene Rigaud, Denis Pérez-Cuesta, Abid Khan, Aline Tobar-Bustamente, Andrea Barrancas, Carla Figueroa-Torres, José Gutiérrez de la Cruz, Francisca Burgos-Alarcón, Jenifer Gómez-Donoso
{"title":"持续的脑雾与COVID-19患者的严重症状群有关。","authors":"José Ramón Lanz-Luces,&nbsp;Héctor Aceituno,&nbsp;Fernando Quiroz-Bravo,&nbsp;Felipe Rodríguez-Flores,&nbsp;Marcela Osores-Espinoza,&nbsp;Dairene Rigaud,&nbsp;Denis Pérez-Cuesta,&nbsp;Abid Khan,&nbsp;Aline Tobar-Bustamente,&nbsp;Andrea Barrancas,&nbsp;Carla Figueroa-Torres,&nbsp;José Gutiérrez de la Cruz,&nbsp;Francisca Burgos-Alarcón,&nbsp;Jenifer Gómez-Donoso","doi":"10.4067/S0034-98872022001101484","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 patients may experience Long-lasting symptoms from weeks to even months.</p><p><strong>Aim: </strong>To evaluate long-term cognitive impairment based on the severity of symptoms of COVID-19 infection in a primary health system setting.</p><p><strong>Material and methods: </strong>From a database of 363 patients, 83 cases aged 47 ± 15 years, (58% females) were selected from June to August 2020. In patients who survived the virus, 24 infection-related symptoms were collected to create three severity clusters (mild, moderate, and severe). The follow-up time was at least seven months. Comparing the first two clusters with the severe cluster, the existence of brain fog and risk factors (obesity, hypertension, diabetes, chronic lung disease, and hypothyroidism) were analyzed.</p><p><strong>Results: </strong>Thirty-one patients (37%) had persistent symptoms lasting up to 240 days. Fifty-one patients (61%) experienced brain fog. Concentration was affected by symptom severity (odds ratio [OR] 3.63, 95% confidence interval [CI] 1.26-10.46, p = 0.02). Short- or long-term memory loss was not affected. Moreover, symptom severity was related to brain fog (OR 3.16, 95% CI 1.05-9.51, p = 0.04). Patients with persistent symptoms had a concentration impairment associated with severity patterns (OR 24.3, 95% CI 1.73-340.11, p = 0.03).</p><p><strong>Conclusions: </strong>Brain fog is associated with symptom severity in COVID-19 survivors and lasts for more than eight months.</p>","PeriodicalId":21360,"journal":{"name":"Revista medica de Chile","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-lasting brain fog is related with severity clusters of symptoms in COVID-19 patients.\",\"authors\":\"José Ramón Lanz-Luces,&nbsp;Héctor Aceituno,&nbsp;Fernando Quiroz-Bravo,&nbsp;Felipe Rodríguez-Flores,&nbsp;Marcela Osores-Espinoza,&nbsp;Dairene Rigaud,&nbsp;Denis Pérez-Cuesta,&nbsp;Abid Khan,&nbsp;Aline Tobar-Bustamente,&nbsp;Andrea Barrancas,&nbsp;Carla Figueroa-Torres,&nbsp;José Gutiérrez de la Cruz,&nbsp;Francisca Burgos-Alarcón,&nbsp;Jenifer Gómez-Donoso\",\"doi\":\"10.4067/S0034-98872022001101484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>COVID-19 patients may experience Long-lasting symptoms from weeks to even months.</p><p><strong>Aim: </strong>To evaluate long-term cognitive impairment based on the severity of symptoms of COVID-19 infection in a primary health system setting.</p><p><strong>Material and methods: </strong>From a database of 363 patients, 83 cases aged 47 ± 15 years, (58% females) were selected from June to August 2020. In patients who survived the virus, 24 infection-related symptoms were collected to create three severity clusters (mild, moderate, and severe). The follow-up time was at least seven months. Comparing the first two clusters with the severe cluster, the existence of brain fog and risk factors (obesity, hypertension, diabetes, chronic lung disease, and hypothyroidism) were analyzed.</p><p><strong>Results: </strong>Thirty-one patients (37%) had persistent symptoms lasting up to 240 days. Fifty-one patients (61%) experienced brain fog. Concentration was affected by symptom severity (odds ratio [OR] 3.63, 95% confidence interval [CI] 1.26-10.46, p = 0.02). Short- or long-term memory loss was not affected. Moreover, symptom severity was related to brain fog (OR 3.16, 95% CI 1.05-9.51, p = 0.04). Patients with persistent symptoms had a concentration impairment associated with severity patterns (OR 24.3, 95% CI 1.73-340.11, p = 0.03).</p><p><strong>Conclusions: </strong>Brain fog is associated with symptom severity in COVID-19 survivors and lasts for more than eight months.</p>\",\"PeriodicalId\":21360,\"journal\":{\"name\":\"Revista medica de Chile\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista medica de Chile\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4067/S0034-98872022001101484\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica de Chile","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4067/S0034-98872022001101484","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:COVID-19患者可能会出现持续数周甚至数月的症状。目的:评估初级卫生系统中基于COVID-19感染症状严重程度的长期认知障碍。材料与方法:选取2020年6 - 8月363例患者,年龄47±15岁83例,其中女性58%。在病毒存活的患者中,收集了24种与感染相关的症状,以创建三个严重程度集群(轻度、中度和重度)。随访时间至少7个月。将前两组与重度组进行比较,分析脑雾的存在情况及危险因素(肥胖、高血压、糖尿病、慢性肺病、甲状腺功能减退)。结果:31例(37%)患者持续症状达240天。51例(61%)患者出现脑雾。浓度受症状严重程度的影响(优势比[OR] 3.63, 95%可信区间[CI] 1.26-10.46, p = 0.02)。短期或长期记忆丧失不受影响。此外,症状严重程度与脑雾有关(OR 3.16, 95% CI 1.05-9.51, p = 0.04)。持续症状患者的浓度损害与严重程度相关(OR 24.3, 95% CI 1.73-340.11, p = 0.03)。结论:脑雾与COVID-19幸存者的症状严重程度有关,且持续时间超过8个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-lasting brain fog is related with severity clusters of symptoms in COVID-19 patients.

Background: COVID-19 patients may experience Long-lasting symptoms from weeks to even months.

Aim: To evaluate long-term cognitive impairment based on the severity of symptoms of COVID-19 infection in a primary health system setting.

Material and methods: From a database of 363 patients, 83 cases aged 47 ± 15 years, (58% females) were selected from June to August 2020. In patients who survived the virus, 24 infection-related symptoms were collected to create three severity clusters (mild, moderate, and severe). The follow-up time was at least seven months. Comparing the first two clusters with the severe cluster, the existence of brain fog and risk factors (obesity, hypertension, diabetes, chronic lung disease, and hypothyroidism) were analyzed.

Results: Thirty-one patients (37%) had persistent symptoms lasting up to 240 days. Fifty-one patients (61%) experienced brain fog. Concentration was affected by symptom severity (odds ratio [OR] 3.63, 95% confidence interval [CI] 1.26-10.46, p = 0.02). Short- or long-term memory loss was not affected. Moreover, symptom severity was related to brain fog (OR 3.16, 95% CI 1.05-9.51, p = 0.04). Patients with persistent symptoms had a concentration impairment associated with severity patterns (OR 24.3, 95% CI 1.73-340.11, p = 0.03).

Conclusions: Brain fog is associated with symptom severity in COVID-19 survivors and lasts for more than eight months.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista medica de Chile
Revista medica de Chile 医学-医学:内科
CiteScore
1.20
自引率
16.70%
发文量
75
审稿时长
3-6 weeks
期刊介绍: La Revista Médica de Chile publica trabajos originales sobre temas de interés médico y de Ciencias Biomédicas, dando preferencia a los relacionados con la Medicina Interna y sus especialidades derivadas. Publicada mensualmente, desde 1872, por la Sociedad Médica de Santiago. La abreviatura de su título es Rev Med Chile, que debe ser usado en bibliografías, notas al pié de página, leyendas y referencias bibliográficas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信